Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

SMMT

Summit Therapeutics (SMMT)

Summit Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SMMT
DateTimeSourceHeadlineSymbolCompany
01/25/20186:51AMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:SMMTSummit Therapeutics Inc
01/25/20186:00AMGlobeNewswire Inc.Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical T...NASDAQ:SMMTSummit Therapeutics Inc
01/09/20186:00AMGlobeNewswire Inc.Summit Therapeutics to Present at the Biotech ShowcaseNASDAQ:SMMTSummit Therapeutics Inc
01/03/201812:47PMEdgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:SMMTSummit Therapeutics Inc
01/03/201812:28PMEdgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:SMMTSummit Therapeutics Inc
01/03/201812:19PMEdgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:SMMTSummit Therapeutics Inc
12/26/20176:27AMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:SMMTSummit Therapeutics Inc
12/23/20173:00PMGlobeNewswire Inc.Summit Obtains Innovative Antibiotic Discovery and Development Platform Through Acquisition of Discuva LtdNASDAQ:SMMTSummit Therapeutics Inc
12/21/20176:31AMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:SMMTSummit Therapeutics Inc
12/06/20173:28PMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:SMMTSummit Therapeutics Inc
12/06/20176:00AMGlobeNewswire Inc.Summit Therapeutics Reports Financial Results for the Third Quarter and Nine Months Ended 31 October 2017 and Operational Pro...NASDAQ:SMMTSummit Therapeutics Inc
12/06/20171:00AMGlobeNewswire Inc.Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy ...NASDAQ:SMMTSummit Therapeutics Inc
12/04/20176:00AMGlobeNewswire Inc.Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2017 on 6 December 201...NASDAQ:SMMTSummit Therapeutics Inc
11/22/20176:00AMGlobeNewswire Inc.Summit Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:SMMTSummit Therapeutics Inc
11/20/20176:00AMGlobeNewswire Inc.Summit Completes Initial 24 Weeks of Dosing of Ezutromid in Patients With DMD in PhaseOut DMD Clinical TrialNASDAQ:SMMTSummit Therapeutics Inc
11/09/20176:00AMGlobeNewswire Inc.Summit Highlights Utrophin Modulation as a Potential Universal Treatment Option in DMD at 15th Action Duchenne International ...NASDAQ:SMMTSummit Therapeutics Inc
11/06/20178:29AMGlobeNewswire Inc.Summit Announces Signing of Revenue Sharing Agreement With the Wellcome Trust for CDI Antibiotic RidinilazoleNASDAQ:SMMTSummit Therapeutics Inc
11/06/20176:01AMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:SMMTSummit Therapeutics Inc
10/25/20178:00AMGlobeNewswire Inc.Grant of Share Options to Directors, PDMRs and Employees and Grant of Restricted Stock Units to Non-Executive DirectorsNASDAQ:SMMTSummit Therapeutics Inc
10/09/20176:00AMGlobeNewswire Inc.Summit Highlights Microbiome Preservation During Ridinilazole Treatment in Exploratory Phase 2 Clinical Trial at ID Week 2017...NASDAQ:SMMTSummit Therapeutics Inc
10/04/20176:00AMGlobeNewswire Inc.Summit Highlights DMD Biomarker Validation Data and Phase 2 Clinical Trial Baseline Characteristics in Presentations at 22nd ...NASDAQ:SMMTSummit Therapeutics Inc
10/02/20176:00AMGlobeNewswire Inc.Summit Therapeutics to Host R&D Day 11 October 2017NASDAQ:SMMTSummit Therapeutics Inc
09/25/20176:00AMGlobeNewswire Inc.Summit Joins cTAP in Collaborative Effort to Enhance the Development of Utrophin Modulators and Other Treatments for Duchenne...NASDAQ:SMMTSummit Therapeutics Inc
09/20/201712:06PMEdgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:SMMTSummit Therapeutics Inc
09/18/20173:49PMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:SMMTSummit Therapeutics Inc
09/15/201712:31PMGlobeNewswire Inc.Summit Therapeutics Announces Exercise of Underwriters’ Over-Allotment OptionNASDAQ:SMMTSummit Therapeutics Inc
09/14/20174:24PMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:SMMTSummit Therapeutics Inc
09/14/20174:21PMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:SMMTSummit Therapeutics Inc
09/13/201710:03PMGlobeNewswire Inc.Summit Therapeutics Announces Pricing of Public Offering of 1,459,000 American Depositary SharesNASDAQ:SMMTSummit Therapeutics Inc
09/13/20173:52PMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:SMMTSummit Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SMMT